Zim Laboratories Ltd
Zim Laboratories Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company expects base business revenues in H2 FY '26 to be in line with last year's numbers, compensating for H1 shortfall. The company expects to achieve last year's revenue numbers in H2 FY '26, compensating for the shortfall in H1.
From Zim Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects base business revenues in H2 FY '26 to be in line with last year's numbers, compensating for H1 shortfall.
- NIP (New Innovative Products) and OTF (Orally Thin Films) sales are anticipated to return to approx. INR 15–16 crores run rate in Q3 and Q4 FY '26.
- India and export order books remain strong, supporting revenue recovery in H2 FY '26 and beyond.
- New Marketing Authorizations (MAs) recently received—especially in ROW markets—are expected to commercialize within 3 to 6 months, driving growth.
- EU-GMP compliance and remediation expected by Q4 FY '26 will enable resumption of EU market sales starting Q1 or Q2 FY '27.
- Management targets 20–25% revenue growth and improved margins (14–15% EBITDA) in FY '27, assuming timely EU sales restart.
2 more points from Zim Laboratories Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Zim Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The previously planned capex has been mostly completed.
- There is a marginal additional capex of around INR 5 crore related to CAPA implementation.
- Another INR 5 to 7 crore is planned for completion of balance capex, with borrowings already tied up.
- No significant further increase in borrowing or capex is expected beyond these amounts.
2 more points from Zim Laboratories Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zim Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has a robust order book with orders already in hand, providing confidence for achieving year-end targets similar to the previous year.
- For innovative products like NIP and OTF, there was a shortfall in H1 due to audit-related prudence delaying order execution, but orders are moderating and expected to compensate in H2.
- Orders that were delayed in H1 for some customers are expected to come in H2, aiming to reach prior run rates of around INR 15-16 crores per quarter for NIP and OTF products.
- The business plan anticipates roughly 60% of annual business in H2, based on existing orders and expected government orders.
2 more points from Zim Laboratories Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Zim Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹105 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zim Laboratories's management said in earlier quarters
Arthneeti Pro · Annual
Zim Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zim Laboratories Ltd Q2 FY26 results?
The company expects base business revenues in H2 FY '26 to be in line with last year's numbers, compensating for H1 shortfall. The company expects to achieve last year's revenue numbers in H2 FY '26, compensating for the shortfall in H1.
What is Zim Laboratories Ltd share price analysis?
Zim Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 141.2 with a market cap of ₹614 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zim Laboratories Ltd planning capital expenditure?
The previously planned capex has been mostly completed.
Keep Zim Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.